ArticleBlood advances2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
abstractEpcoritamab is a US Food and Drug Administration-approved bispecific antibody for relapsed/refractory (R/R) large B-cell lymphomas (BCLs). Real-world outcomes and safety data remain limited. We analyzed 157 adult patients with R/R aggressive BCLs who received epcoritamab outside of a clinical trial between 2023 and 2025 at 9 centers in the Collaborative US Bispecific Consortium. The best overall response rate (ORR) was 49.6%, and the best complete response rate (CRR) was 31.9%. With a median follow-up of 15.8 months, the 1-year progression-free survival (PFS) and overall survival (OS) rates among all patients were 29% (95% confidence interval [CI], 22-37) and 38% (95% CI, 31-47), respectively. Inferior ORRs and CRRs were observed in patients with high International Prognostic Index, elevated lactate dehydrogenase (LDH), ≥2 extranodal sites, and disease refractory to the previous line of therapy (LOT). In multivariable analysis, Eastern Cooperative Oncology Group performance status score of ≥2, elevated LDH, refractory disease to previous LOT, and clinical trial ineligibility were associated with inferior PFS and OS. Among all patients, 33% had any-grade cytokine release syndrome (CRS; grade ≥3, 4.6%), whereas immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 12% (grade ≥3, 0.6%) of patients. Intensive care unit (ICU) admission occurred in 17% of patients. Compared with pivotal trials and other real-world studies, we observed inferior response rates and survival outcomes as well as higher rates of grade ≥3 CRS, any-grade ICANS, and ICU admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.